Real-life Experiences from a Late Effects Clinic in Denmark

Lærke K. Tolstrup1,2, Karin B. Dieperink1,2, Line H. Clausen1, Linee Fechner1, Thea O. Mattsson1

1Department of Oncology, Odense University Hospital (1) Department of Clinical Research, University of Southern Denmark (2)

Patients consulting a late effects clinic after cancer and/or its treatment report unmet needs and a low quality of life!

Can we help these patients to a better life after cancer?

INTRODUCTION

More than 50% of cancer survivors experience one or more late effects from their cancer and its treatment—many report unmet needs that negatively affect their health-related quality of life (HRQol).

We elucidate the range of late effects occurring in the patients referred to a late effects clinic and the effect on their pre-visit HRQol by the use of patient-reported outcomes (PRO).

RESULTS

• N=195
• Age: 57 years [26-85], 75% Female
• Time from diagnosis: 3 years
• Most common diagnoses: Breast cancer (40%)
• Significantly lower HRQol compared to norm data
• 60% have 4 or more late effects

METHODS

• Prospective study including all patients consulting the Late Effects Clinic,

• PRO-data - EORTC QLQ-SURV100 questionnaire:
  • prior to first consultation (dialogue tool)
  • end-of-treatment
  • at 6, 12, and 24 months after end-of-treatment

• Baseline data – collected in RedCap database
  • age, gender, diagnoses
  • number and type of late effect
  • living alone or with partner

PERSPECTIVES

By measuring the patients’ HRQol prospectively by the use of EORTC SURV100, we will be able to evaluate the effect on interventions imitated in the late effects clinic.

RESULTS

• Age: 57 years [26-85], 75% Female
• Time from diagnosis: 3 years
• Most common diagnoses: Breast cancer (40%)
• Significantly lower HRQol compared to norm data
• 60% have 4 or more late effects

METHODS

• Prospective study including all patients consulting the Late Effects Clinic,

• PRO-data - EORTC QLQ-SURV100 questionnaire:
  • prior to first consultation (dialogue tool)
  • end-of-treatment
  • at 6, 12, and 24 months after end-of-treatment

• Baseline data – collected in RedCap database
  • age, gender, diagnoses
  • number and type of late effect
  • living alone or with partner

PERSPECTIVES

By measuring the patients’ HRQol prospectively by the use of EORTC SURV100, we will be able to evaluate the effect on interventions imitated in the late effects clinic.

RESULTS

• Age: 57 years [26-85], 75% Female
• Time from diagnosis: 3 years
• Most common diagnoses: Breast cancer (40%)
• Significantly lower HRQol compared to norm data
• 60% have 4 or more late effects